Ruxolitinib Remains Backbone in Myelofibrosis and MPN Treatment

Via Peters

Patients with myelofibrosis and other myeloproliferative neoplasms (MPN) are often able to achieve improved survival outcomes and quality of life following treatment with ruxolitinib (Jakafi), a highly potent and selective JAK inhibitor, alone and in combination with other drugs. Despite this, treatment options designed to address disease progression itself are […]